FDAnews
www.fdanews.com/articles/146658-phase-ii-trial-used-ambulatory-blood-pressure-monitoring-to-evaluate-blood-pressure

Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure

May 23, 2012
Eli Lilly announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 analog being studied as a once-weekly treatment for Type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.
The Financial